Home -> Law Blog Directory -> Intellectual Property Law Blogs -> TinytechIP
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: TinytechIPUS Patent 7758889 - Fullerene in targeted therapies
This patent from Luna Innovations (priority 7/18/2003) includes some basic claims to using fullerenes or carbon nanotubes for drug delivery. Claim 1 reads:
1. A composition, comprising: (i) a Cn-Ab, wherein Cn is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the Cn, wherein the antigen-binding site recognizes an antigen associated with a medical condition; and (ii) a pharmaceutically-acceptable carrier.
Full post as published by TinytechIP on July 21, 2010 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Sony
to Pay $18.5 Million For Patent Infringment
Qualcomm Settles Patent Suit for $891 Million
The Princeton Review
$2.6 million settlement reached in patent infringement case.

"Patent Appeals Board Constitutionality Targeted in Federal Circuit"
Integrating complementary therapies into mainstream medicine
Mainstreaming Complementary Therapies: New Directions In Health Care
SEC Settles Fraud Charges Against Former Transkaryotic Therapies CEO
Patent Examiner Experience Levels
Targeted Cancer Drugs Cause Heart Trouble









